AU2017228870B2 - Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections - Google Patents

Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections Download PDF

Info

Publication number
AU2017228870B2
AU2017228870B2 AU2017228870A AU2017228870A AU2017228870B2 AU 2017228870 B2 AU2017228870 B2 AU 2017228870B2 AU 2017228870 A AU2017228870 A AU 2017228870A AU 2017228870 A AU2017228870 A AU 2017228870A AU 2017228870 B2 AU2017228870 B2 AU 2017228870B2
Authority
AU
Australia
Prior art keywords
alkyl
tert
optionally substituted
heta
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017228870A
Other languages
English (en)
Other versions
AU2017228870A1 (en
Inventor
Reynalda Keh Dejesus
Fa-Xiang Ding
Yan Guo
Xianhai Huang
Jinlong JIAN
Weiguo Liu
Wanying Sun
Haifeng Tang
Hongwu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of AU2017228870A1 publication Critical patent/AU2017228870A1/en
Application granted granted Critical
Publication of AU2017228870B2 publication Critical patent/AU2017228870B2/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017228870A 2016-03-07 2017-03-02 Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections Active AU2017228870B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662304447P 2016-03-07 2016-03-07
US62/304,447 2016-03-07
PCT/US2017/020303 WO2017155765A1 (en) 2016-03-07 2017-03-02 Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
AU2017228870A1 AU2017228870A1 (en) 2018-09-06
AU2017228870B2 true AU2017228870B2 (en) 2021-02-18

Family

ID=59789685

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017228870A Active AU2017228870B2 (en) 2016-03-07 2017-03-02 Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Country Status (12)

Country Link
US (1) US10407421B2 (enExample)
EP (1) EP3426248B1 (enExample)
JP (1) JP7034929B2 (enExample)
KR (1) KR102408800B1 (enExample)
CN (1) CN108778273B (enExample)
AU (1) AU2017228870B2 (enExample)
BR (1) BR112018067930B1 (enExample)
CA (1) CA3016341A1 (enExample)
MA (1) MA43811A (enExample)
MX (1) MX2018010878A (enExample)
RU (1) RU2733402C2 (enExample)
WO (1) WO2017155765A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
GEAP202215303A (en) * 2017-10-02 2022-04-11 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
EP3747883A4 (en) * 2018-01-29 2020-12-16 Medshine Discovery Inc. MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
US20220002288A1 (en) * 2018-11-13 2022-01-06 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
WO2020125670A1 (zh) * 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN110963967B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种2-甲基-4-氨基喹啉的制备方法
CN111018777B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种地喹氯铵的制备方法
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
US11780832B2 (en) 2021-03-31 2023-10-10 Fedora Pharmaceuticals Inc. Lactivicin compounds, their preparation and use as antibacterial agents
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
KR20250093507A (ko) * 2022-11-07 2025-06-24 고쿠리츠 다이가쿠 호진 교토 다이가쿠 퀴나졸린 유도체
CN121955228A (zh) * 2025-12-31 2026-05-01 北京大学人民医院 同时检测亚胺培南、雷利巴坦和西司他丁的方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531976A1 (en) * 1991-09-09 1993-03-17 E.R. SQUIBB & SONS, INC. Heteroaryl derivatives of monocyclic beta-lactam antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684722A (en) 1986-01-06 1987-08-04 E. R. Squibb & Sons, Inc. Monosulfactams
MY127641A (en) 1995-10-12 2006-12-29 Essential Therapeutics Inc Cephalosporin antibiotics
RU2269525C2 (ru) * 2000-08-10 2006-02-10 Бритиш Биотех Фармасьютикалс Лимитед Антибактериальные агенты
KR101403164B1 (ko) 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
JP5777725B2 (ja) 2010-11-29 2015-09-09 ファイザー・インク モノバクタム
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
US20140275007A1 (en) 2013-03-14 2014-09-18 Rempex Pharmaceuticals, Inc. Oxamazin antibiotics
HUE042134T2 (hu) 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531976A1 (en) * 1991-09-09 1993-03-17 E.R. SQUIBB & SONS, INC. Heteroaryl derivatives of monocyclic beta-lactam antibiotics

Also Published As

Publication number Publication date
MX2018010878A (es) 2018-11-09
CN108778273B (zh) 2022-06-17
WO2017155765A1 (en) 2017-09-14
KR20180121948A (ko) 2018-11-09
US10407421B2 (en) 2019-09-10
CA3016341A1 (en) 2017-09-14
JP2019507768A (ja) 2019-03-22
MA43811A (fr) 2018-11-28
EP3426248A1 (en) 2019-01-16
RU2018134948A (ru) 2020-04-08
RU2733402C2 (ru) 2020-10-01
BR112018067930A2 (pt) 2019-01-22
EP3426248A4 (en) 2019-07-10
RU2018134948A3 (enExample) 2020-04-08
US20190071436A1 (en) 2019-03-07
JP7034929B2 (ja) 2022-03-14
BR112018067930A8 (pt) 2023-04-11
KR102408800B1 (ko) 2022-06-13
BR112018067930B1 (pt) 2024-02-15
EP3426248B1 (en) 2023-11-15
CN108778273A (zh) 2018-11-09
AU2017228870A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
US11230543B2 (en) Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN108778273B (zh) 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法
AU2018345523B2 (en) Chromane monobactam compounds for the treatment of bacterial infections
AU2013211575A1 (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
BR112020006381B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
HK40029711A (en) Chromane monobactam compounds for the treatment of bacterial infections
HK40029711B (en) Chromane monobactam compounds for the treatment of bacterial infections
BR112018010962B1 (pt) Composto, sal de ácido trifluoroacético, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.